TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04387773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GOCOVRI
Description: Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group.
Study: NCT01393964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT04523207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
Study: NCT00589771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks
Study: NCT04552366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Description: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Description: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad5-nCoV
Description: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Description: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Study: NCT02189057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AssureRx GeneSight genotyping results

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study: NCT01393964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT01478334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Description: First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period.
Study: NCT01393964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT03240471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One week of plaster cast
Description: One week of plaster cast as treatment for a non-reduced distal radius fracture.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Four-Five weeks of plaster cast
Description: Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
Study: NCT02217891

Intervention type: BEHAVIORAL
Intervention: Semi-structured interview
Description: Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, \& qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits \& harms of tumor genomic profiling; 2) interest in \& perceived benefits \& harms of incidental findings arising from tumor genomic profiling; 3) anticipated process \& needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, \& those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; \& 6) implications of \& concerns about incidental findings for family.
Study: NCT01478334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.
Study: NCT03158103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 at 30mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
Study: NCT00947921

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasty
Description: Restrictive Annuloplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis
Description: Valve replacement
Study: NCT04371380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets
Description: Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Tablets
Description: Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
Study: NCT00627159

Intervention type: OTHER
Group type: OTHER
Intervention: High risk assessment
Description: For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.

Intervention type: OTHER
Group type: OTHER
Intervention: Low to moderate risk
Description: For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
Study: NCT02382003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Cognitive Bias Modification - Interpretation
Description: Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Cognitive Bias Modification - Interpretation
Description: Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 50/50 Cognitive Bias Modification - Interpretation
Description: This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 50/50 Cognitive Bias Modification - Interpretation
Description: This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxious Imagery Prime
Description: We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Anxious Imagery Prime
Description: We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxious Imagery Prime
Description: We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.
Study: NCT01744548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tCBT treatment
Description: The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
Study: NCT01964963

Intervention type: DRUG
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT00971074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Description: 6 ml intra-articular injection given once. The injection takes approximately 15 seconds.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: A needle will be inserted through the knee capsule but no medication will be injected.
Study: NCT00242541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate
Study: NCT03723772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGlar U100
Description: Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGlar U100
Description: Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
Study: NCT04675502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised Exercise training
Description: warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise trainig
Description: Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
Study: NCT02032394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Description: 15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
Study: NCT02382003

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Imagery Prime
Description: At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neutral Imagery Prime
Description: At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Imagery Prime
Description: At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
Study: NCT02032394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
Study: NCT03076710

Intervention type: DRUG
Intervention: Opioids delivered through PCA
Description: IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours

Intervention type: DRUG
Intervention: EXPAREL® infiltration
Description: 22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request
Study: NCT04503655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI.
Study: NCT04004299

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HCV RNA self-test
Description: Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
Study: NCT02282839

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Powder that soluble in water for drinking, 10g TID (total 30 g per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
Study: NCT01013116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified allergen extract of house dust mites
Description: subcutaneous injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injections
Study: NCT04112108

Intervention type: PROCEDURE
Intervention: PTMC
Description: percutaneous mitral ballooning with Inoue balloon
Study: NCT04017416

Intervention type: BEHAVIORAL
Intervention: I-PLAN
Description: The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
Study: NCT02503969

Intervention type: OTHER
Intervention: Exposure to having a long-term condition.
Description: Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer.
Study: NCT00806429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal appendectomy
Description: patient undergoes transvaginal appendectomy
Study: NCT03575507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL EMSCULPT device.
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
Study: NCT02188745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17B-estradiol
Description: Anti-estrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
Study: NCT01092715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: Non thrust mobilization to the cervical spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Sedative massage to cervical paraspinal muscles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neck exercises
Description: Range of motion exercises to include foraminal opening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck exercises
Description: Range of motion exercises to include foraminal opening
Study: NCT03744858

Intervention type: PROCEDURE
Intervention: Peripheral blood draw
Description: Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.

Intervention type: PROCEDURE
Intervention: Peripheral blood draw
Description: Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.